These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 1827708)
41. Complementary DNA libraries and neurological disease. Joseph B; Furneaux H Arch Neurol; 1998 Jun; 55(6):785-8. PubMed ID: 9626768 [No Abstract] [Full Text] [Related]
42. Huntington's disease: genetically programmed cell death in the human central nervous system. Martin JB Nature; 1982 Sep; 299(5880):205-6. PubMed ID: 6213865 [No Abstract] [Full Text] [Related]
43. [Present status of neurology in 1979]. Autret A Rev Prat; 1979 Jun; 29(35):2751-68. PubMed ID: 158824 [No Abstract] [Full Text] [Related]
44. Pathobiology of neuronal storage disease. Walkley SU Int Rev Neurobiol; 1988; 29():191-244. PubMed ID: 3042663 [No Abstract] [Full Text] [Related]
45. Genomics and degenerative diseases of the nervous system. Martin JB J Law Med Ethics; 2000; 28(4 Suppl):30-8. PubMed ID: 11244842 [No Abstract] [Full Text] [Related]
46. From spontaneous to induced neurological mutations: a personal witness of the ascent of the mouse model. Rakic P Results Probl Cell Differ; 2000; 30():1-19. PubMed ID: 10857183 [No Abstract] [Full Text] [Related]
47. Re-thinking the brain: a frog leaps. Bax MC Dev Med Child Neurol; 2002 Nov; 44(11):723. PubMed ID: 12418610 [No Abstract] [Full Text] [Related]
52. The cytoprotective effects of dantrolene: a ryanodine receptor antagonist. Inan S; Wei H Anesth Analg; 2010 Dec; 111(6):1400-10. PubMed ID: 20861418 [TBL] [Abstract][Full Text] [Related]
53. The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration. Yamamoto A; Simonsen A Neurobiol Dis; 2011 Jul; 43(1):17-28. PubMed ID: 20732422 [TBL] [Abstract][Full Text] [Related]
54. A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. Zabel C; Mao L; Woodman B; Rohe M; Wacker MA; Kläre Y; Koppelstätter A; Nebrich G; Klein O; Grams S; Strand A; Luthi-Carter R; Hartl D; Klose J; Bates GP Mol Cell Proteomics; 2009 Apr; 8(4):720-34. PubMed ID: 19043139 [TBL] [Abstract][Full Text] [Related]
56. Transcriptional signatures in Huntington's disease. Cha JH Prog Neurobiol; 2007 Nov; 83(4):228-48. PubMed ID: 17467140 [TBL] [Abstract][Full Text] [Related]
57. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. Leegwater-Kim J; Cha JH NeuroRx; 2004 Jan; 1(1):128-38. PubMed ID: 15717013 [TBL] [Abstract][Full Text] [Related]
58. Expression of normal and mutant huntingtin in the developing brain. Bhide PG; Day M; Sapp E; Schwarz C; Sheth A; Kim J; Young AB; Penney J; Golden J; Aronin N; DiFiglia M J Neurosci; 1996 Sep; 16(17):5523-35. PubMed ID: 8757264 [TBL] [Abstract][Full Text] [Related]
59. Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine. Mayeux R; Schupf N Am J Public Health; 1995 Sep; 85(9):1280-4. PubMed ID: 7661240 [TBL] [Abstract][Full Text] [Related]
60. Dopamine receptor genes: new tools for molecular psychiatry. Niznik HB; Van Tol HH J Psychiatry Neurosci; 1992 Oct; 17(4):158-80. PubMed ID: 1450188 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]